Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:April 27, 2018Completed
Hide Studies Not Open or Pending
Condition(s):Multiple MyelomaLast Updated:April 27, 2018Completed
Condition(s):Multiple MyelomaLast Updated:January 18, 2017Completed
Condition(s):Multiple Myeloma; Relapse After Use of Lenalidomide and BortezomibLast Updated:May 17, 2018Unknown status
Condition(s):Multiple MyelomaLast Updated:May 10, 2016Withdrawn
Condition(s):Lymphoma; Multiple MyelomaLast Updated:February 23, 2024Active, not recruiting
Condition(s):Waldenstrom Macroglobulinemia; Multiple Myeloma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Lymphoplasmacytic Lymphoma; Marginal Zone Lymphoma; Mantle Cell Lymphoma; Diffuse Large B Cell Lymphoma; Central Nervous System LymphomaLast Updated:January 22, 2024Recruiting
Condition(s):Leukemia; Lymphoma; Multiple Myeloma of Bone (Diagnosis)Last Updated:January 9, 2019Unknown status
Condition(s):Multiple Myeloma in RemissionLast Updated:October 12, 2023Recruiting
Condition(s):Relapsed Multiple MyelomaLast Updated:January 20, 2021Completed
Condition(s):Multiple MyelomaLast Updated:September 21, 2023Active, not recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.